Tamgiblimab
Tamgiblimab (IBI939) is a fully human monoclonal antibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) . Tamgiblimab has anticancer effects[1].
Product Specifications
CAS Number
2411914-36-6
Product Name Alternative
IBI939
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tamgiblimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Tamgiblimab]
Molecular Weight
(144.34 kDa)
References & Citations
[1]Y. Cheng, et al. 77P A study to evaluate the safety, tolerability and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) . Immuno-Oncology and Technology. DECEMBER 01, 2022.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![(1’S,2R)-2-[(1’,2’-O-Isopropylidene)dihydroxyethyl]-6-fluorochroman-4-one](https://cdn.genprice.uk/products/572/3981918432249/imageurl/trc-i824945-250mg.webp)
TRC-I824945-250MG 250 mg
(1’S,2R)-2-[(1’,2’-O-Isopropylidene)dihydroxyethyl]-6-fluorochroman-4-one
Sign In for Pricing
View Details 
TRC-C988520-50MG 50 mg
1-Cyclopropyl-8-ethoxy-6,7-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid
Sign In for Pricing
View Details